Poseida Therapeutics Inc. (NASDAQ: PSTX) has experienced a decline in its stock price by -7.45 compared to its previous closing price of 2.55. However, the company has seen a fall of -6.35% in its stock price over the last five trading days.
Is It Worth Investing in Poseida Therapeutics Inc. (NASDAQ: PSTX) Right Now?
There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
The average price predicted by analysts for PSTX is $13.40, which is $11.04 above the current price. The public float for PSTX is 60.34M and currently, short sellers hold a 7.52% ratio of that float. The average trading volume of PSTX on May 26, 2023 was 739.57K shares.
PSTX’s Market Performance
PSTX stock saw a decrease of -6.35% in the past week, with a monthly decline of -3.67% and a quarterly a decrease of -59.59%. The volatility ratio for the week is 11.72%, and the volatility levels for the last 30 days are 10.25% for Poseida Therapeutics Inc. (PSTX). The simple moving average for the past 20 days is -17.81% for PSTX’s stock, with a -47.43% simple moving average for the past 200 days.
PSTX Trading at -20.90% from the 50-Day Moving Average
After a stumble in the market that brought PSTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.24% of loss for the given period.
Volatility was left at 10.25%, however, over the last 30 days, the volatility rate increased by 11.72%, as shares sank -2.07% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -43.27% lower at present.
During the last 5 trading sessions, PSTX fell by -6.35%, which changed the moving average for the period of 200-days by -35.16% in comparison to the 20-day moving average, which settled at $2.87. In addition, Poseida Therapeutics Inc. saw -55.47% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at PSTX starting from Malin Life Sciences Holdings L, who purchase 2,150,000 shares at the price of $3.50 back on Aug 08. After this action, Malin Life Sciences Holdings L now owns 11,835,673 shares of Poseida Therapeutics Inc., valued at $7,525,000 using the latest closing price.
Ostertag Eric, the Executive Chairman of Poseida Therapeutics Inc., purchase 142,857 shares at $3.50 during a trade that took place back on Aug 08, which means that Ostertag Eric is holding 838,824 shares at $500,000 based on the most recent closing price.
Stock Fundamentals for PSTX
Current profitability levels for the company are sitting at:
- -86.40 for the present operating margin
- +96.04 for the gross margin
The net margin for Poseida Therapeutics Inc. stands at -49.05. The total capital return value is set at -45.67, while invested capital returns managed to touch -26.58.
Based on Poseida Therapeutics Inc. (PSTX), the company’s capital structure generated 47.31 points at debt to equity in total, while total debt to capital is 32.12. Total debt to assets is 24.58, with long-term debt to equity ratio resting at 44.18. Finally, the long-term debt to capital ratio is 29.99.
When we switch over and look at the enterprise to sales, we see a ratio of 0.20, with the company’s debt to enterprise value settled at 0.47. The receivables turnover for the company is 28.72 and the total asset turnover is 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.54.
In conclusion, Poseida Therapeutics Inc. (PSTX) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.